Automate Your Wheel Strategy on CAPR
With Tiblio's Option Bot, you can configure your own wheel strategy including CAPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CAPR
- Rev/Share 0.293
- Book/Share 2.2966
- PB 2.7257
- Debt/Equity 0.0421
- CurrentRatio 4.3711
- ROIC -0.671
- MktCap 286188420.0
- FreeCF/Share -0.7615
- PFCF -8.2223
- PE -4.0891
- Debt/Assets 0.0331
- DivYield 0
- ROE -0.6271
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CAPR | Alliance Global Partners | -- | Buy | -- | $20 | June 30, 2025 |
| Initiation | CAPR | B. Riley Securities | -- | Buy | -- | $21 | June 26, 2025 |
| Initiation | CAPR | Roth Capital | -- | Buy | -- | $31 | May 20, 2025 |
| Initiation | CAPR | Piper Sandler | -- | Overweight | -- | $35 | Oct. 21, 2024 |
News
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Published: September 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Published: September 09, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)---- $CAPR #CAPR--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On July 11, 2025, Capricor issued a press re.
Read More
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued a statement regarding the U.S. Food and Drug Administration's (FDA) public posting of its Complete Response Letter (CRL) for the Biologics License Application (BLA) for Deramiocel, the Company's investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: September 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR).
Read More
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
Published: September 08, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Sept. 8, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Read More
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
Read More
September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR
Published: September 05, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.
Read More
The Gross Law Firm Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 – CAPR
Published: September 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR).
Read More
September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.
Read More
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of September 15, 2025 Lead Plaintiff Deadline in the Capricor Therapeutics, Inc. (CAPR) Class Action – Investors With Significant Losses Encouraged to Contact the Firm
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor's four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.
Read More
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
Read More
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
Published: August 29, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the "Class Period"), of the important September 15, 2025 lead plaintiff deadline. So what: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Published: August 29, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Capricor To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Capricor between October 9, 2024 and July 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here to find out if you qualify for the class action] NEW YORK , Aug. 29, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Capricor between October 9, 2024 and July 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ("Capricor" or the …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - CAPR
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025.
Read More
ROSEN, A TOP RANKED LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline.
Read More
CAPR LAWSUIT ALERT: The Gross Law Firm Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR).
Read More
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: August 21, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 21, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 9, 2024, and July 10, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: August 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2025 Earnings Conference August 13, 2025 4:30 PM ET Company Participants Anthony J. Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Catherine Clare Novack - JonesTrading Institutional Services, LLC, Research Division Edward Andrew Tenthoff - Piper Sandler & Co., Research Division Joseph Pantginis - H.C.
Read More
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) should contact The Gross Law Firm about pending Class Action - CAPR
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 9, 2024, and July 10, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2025.
Read More
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR
Published: August 15, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025.
Read More
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Published: August 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
About Capricor Therapeutics, Inc. (CAPR)
- IPO Date 2007-02-13
- Website https://www.capricor.com
- Industry Biotechnology
- CEO Linda Marbán
- Employees 160